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Abstract
Inflammation is part of the normal host response to infection and injury. Eicosanoids, cytokines, chemokines, adhesion molecules and
other inflammatory molecules are frequently produced during this process. Numerous studies in humans have documented the inflam-
mation-limiting properties of omega-3 fatty acids, but only a few have been randomised clinical trials. The aim of this study was to perform
a systematic search of randomised clinical trials on omega-3 fatty acids and inflammatory biomarkers in all subjects including healthy and ill
persons up to February 2011 using PubMed and LILACS databases, defined by a specific equation using MeSH terms and limited to ran-
domised clinical trials; there was no any a priori decision to include some diseases and not others. The quality of each publication was
validated by using the JADAD scale and the CONSORT checklist. Inflammatory biomarkers were considered as primary outcomes.
Twenty-six publications of the last 10 years were selected. Studies included healthy subjects and patients with cardiovascular disease
and other chronic and acute diseases; all reported the number of subjects, type of study, type and doses of omega-3 fatty acids, main out-
comes and major inflammatory biomarkers. Dietary omega-3 fatty acids are associated with plasma biomarker levels, reflecting lower levels
of inflammation and endothelial activation in cardiovascular disease and other chronic and acute diseases, including chronic renal disease,
sepsis and acute pancreatitis. However, further research is required before definitive recommendations can be made about the routine use
of omega-3 fatty acids in critically ill patients or with neurodegenerative or chronic renal disease.
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Introduction
Inflammation is an ordered sequelae of events engineered to
maintain tissue and organ homeostasis. The timely release of
mediators and expression of receptors is essential to complete
the programme and restore tissues ad integrum. Inflammation
is characterised by redness, swelling, heat, pain and numerous
physiological changes, including increased blood flow and
permeability across blood capillaries. These changes allow
large molecules to leave the bloodstream and cross the endo-
thelial wall, increasing the migration of leukocytes from the
bloodstream into the surrounding tissue. Inflammation results
from immunological processes in response to injury, invading
pathogens, allergens and toxins and leads to repair of the
damaged tissue. The first cells detected at inflamed sites are
granulocytes, monocytes and macrophages, which have a
role in killing pathogens and clearing cellular and tissue
debris as well as in tissue repair; lymphocytes appear at a
later stage(1–3).
Inflammation can be classified into two types: a) acute inflam-
mation, with a rapid course (from minutes to a few days), in
which the most important events are oedema and the migration
of leukocytes, mainly granulocytes and monocytes; and
b) chronic inflammation, characterised by a long time course,
the presence of lymphocytes and macrophages and the pro-
liferation of blood vessels and connective tissue. Hence, an
exaggerated inflammatory response can cause local tissue
damage and remodelling, which may induce significant and
chronic injury. Inflammation underlies and/or accompanies
numerous prevalent diseases, including cardiovascular diseases,
obesity, diabetes, cancer, inflammatory bowel diseases, neuro-
degenerative diseases, rheumatoid arthritis and asthma(4,5).
The inflammatory response is regulated by a complex
network of mediators. Active mediators modify tissues and
organs and specifically adapt their response to each inflam-
matory inducer signal; these signals increase the production
of inflammatory mediators(6).
Chemical mediators of inflammation (CMFs) have been
described as biomarkers of inflammation for both healthy indi-
viduals and patients with chronic disease(6,7). There are eight
CMF groups: acute phase protein reactants (C-reactive protein
[CRP]), vasoactive amines, vasoactive peptides, fragments of
complement components (C3a, C4a; C5a), lipid mediators
(eicosanoids, docosanoids and platelet-activating factors),
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cytokines, chemokines and proteolytic enzymes(8). Reactive
free radicals, particularly reactive oxygen species (ROS) are
major mediators of various acute and chronic inflammatory
conditions(9)
Bacterial endotoxins can directly activate monocytes and
macrophages, inducing them to form: cytokines, e.g., tumour
necrosis factor (TNF-a), interleukins (IL-1, IL-6, IL-8); chemo-
kines, e.g., monocyte chemotactic protein 1 (MCP-1) and
macrophage inflammatory protein 1 alpha (MIP-1a); eicosa-
noids, e.g., PGE2 and LTB4; nitric oxide; matrix metalloprotei-
nases (MMPs) and other mediators, which also regulate body
response to infection and injury. In addition to eicosanoids, a
number of long-chain polyunsaturated fatty acid (LC-PUFA)
derivatives are involved in resolving the inflammatory process,
notably lipoxins, resolvins and protectins, recently described as
major biomarkers of inflammation(8,10,11).
When TNF-a, IL-1 and IL-6 are present in high concen-
trations, they are especially destructive and implicated in
pathological responses in endotoxic shock, in acute respirat-
ory distress syndrome, and in chronic inflammatory diseases,
e.g., rheumatoid arthritis and inflammatory bowel disease.
Chronic overproduction of TNF-a and IL-1 can damage adi-
pose tissue and muscle and produce loss of bone mass.
Anti-inflammatory cytokines (e.g., IL-10) and receptor antag-
onists (e.g., IL-1R) oppose the cascade of inflammatory
mediators initiated by inflammatory cytokines(3–12).
In addition to CMFs, upregulation of adhesion molecules on
the endothelial cell surface allows leukocyte binding and sub-
sequent diapedesis and is a well-known step of inflammation
in some chronic diseases, e.g., cardiovascular diseases; these
molecules include intercellular adhesion molecule 1 (ICAM-
1), vascular cell adhesion molecule 1 (VCAM-1) and E-Selec-
tin(2,12–15).
The ability of dietary omega-3 LC-PUFA to limit inflam-
mation has been demonstrated in numerous studies of animals
and humans under different conditions and using varied
doses. Its intake is associated with reduced concentrations of
CRP, proinflammatory eicosanoids, cytokines, chemokines
and other inflammation biomarkers(15). However, only some
of these studies were properly designed to provide evidence
of the influence of dietary omega-3 intake on specific inflam-
matory biomarkers. The aim of the present review was to sys-
tematically review evidence on the effect of dietary omega-3
fatty acid (FA) supplementation on inflammatory biomarkers
in healthy subjects and in patients with chronic and acute
inflammatory diseases.
Methods
The research question in this systematic review was “Does
omega-3 LC-PUFA affect biological levels of inflammatory
biomarkers?” It included all randomised controlled trials
(RCTs) in humans, both healthy and ill subjects, in which
the effect of omega-3 LC-PUFA on fluid (mainly plasma or
serum and cerebrospinal fluid) and cellular levels of inflam-
matory biomarkers was compared with that of placebo;
inflammatory biomarkers were considered as primary out-
comes. RCTs with prospective, parallel or crossover designs
were all considered. The papers, or at least the abstract, had
to be in English, but there was no restriction on publication
type or sample size. We did not include any cohort, ecological
or case-control study.
Inclusion and exclusion criteria
For a study to be considered, dietary supplementation or a
specific diet had to be administered, excluding those on diet-
ary recommendations or self-reporting alone. Studies were
also excluded if a supplement was administered that could
potentially leads to confounding the effects of omega-3 fatty
acids (FA) and if there was no ethical approval. Particularly,
five studies in which arginine and omega-3 FA were used
together as supplement sources were excluded.
Participants
Eligible participants were individuals of all ages, either healthy
or with acute or chronic disease. There was no restriction on
the basis of gender, ethnicity, study setting or other
characteristics.
Types of intervention
LC-PUFA treatments were selected, including eicosapentae-
noic acid (EPA), docosahexaenoic acid (DHA) or docosapen-
taenoic acid (DPA), either individually or in combination
with each other or with another pharmacological treatment
(or vitamin supplementation) if the study design allowed the
effect of omega-3 FA to be isolated. There were no restrictions
with regard to dosage or dose regimen.
Primary outcome measures
These had to include changes in the following inflammatory
biomarkers: acute phase reactant proteins (PCR), eicosanoids
(PGE1, PGE2, LTB4, F2-isoprostanes), cytokines (IL-1a, IL-1b,
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF-a, inter-
feron-d), chemokines (CCL2, CCL3, CCL5, CCL11), adhesion
molecules (sVCAM-1, sICAM-1, sE-selectin, sP-selectin) and
related biofactors (sIL-1RII; sIL-6R, sTNF-Rs 1 and 2, CD11b,
CD18, CD49, CCR2 and CCR5, MMP-7, MMP-9, MMP-12,
TIMP-2, a1-ntichymotrypsin, fibrinogen, PAI-1, orosomucoid
AGP), comparing measurements between baseline and the
end of the intervention. Studies that did not evaluate inflam-
matory biomarkers were excluded.
Main stages of the systematic review
The main stages in the classification of studies for this systema-
tic review are depicted in Fig. 1. Studies were identified on the
PubMed database on February 11, 2011, without restriction on
publication date until the search date, using the following
equation: #1 “Fatty Acids, Omega-3”[MeSH] AND “Inflamma-
tion”[MeSH], which yielded 365 different articles. Next, the
equation was modified to: #2 “Fatty Acids, Omega-3”[MeSH]
AND “Inflammation”[MeSH] AND “humans”[MeSH Terms],


























ranada , on 10 Jun 2020 at 08:33:44 , subject to the Cam
bridge Core term






yielding 172 results. A more specific search was then con-
ducted for RCTs, using:#3 “Fatty Acids, Omega-3”[MeSH]
AND “Inflammation”[MeSH] AND “humans”[MeSH Terms]
NOT “Review “[All Fields] AND “Randomised Controlled
Trial” [ptyp]. This search generated 58 original articles, out of
which 26 met all requirements for inclusion in the review.
The LILACS database was also searched on February 11 2011
but yielded no results.
A tool, known as SYSCOLLAB (see Chapter 1), was devel-
oped and used for the selection, classification and validation
of these articles, following the procedures described below.
Study Selection. Abstracts of references obtained by the
search were examined by four reviewers (AG, CMA, MDM,
ODR), who eliminated all references evidently ineligible for
inclusion. Each reviewer studied all of the remaining full
texts independently and made a selection. In cases of dis-
agreement, a consensus was reached on the final list after dis-
cussion among all four reviewers.
Data extraction. Two reviewers (AG, ODR) introduced the
data into a database, and discrepancies between them were
resolved by a third reviewer (CMA). Missing data were obtained
from the authors whenever possible, solicited on specific forms
to avoid bias.
Assessment of quality. The quality of each publication was
validated by applying the JADAD scale and the CONSORT
checklist for clinical trials(16,17)JADAD establishes the quality
level according to five items(16) and the use of the CONSORT
checklist ensures that publications follow quality guidelines.
We developed a quantitative scale by assigning a value to
each item in the list, as shown in Table 1, giving a quality
score ranging from 0 to 30 (low to excellent).
Results
Table 2 lists the 26 publications selected for inclusion in the
review, grouped according to study population (healthy, car-
diovascular disease, other chronic diseases and acute disease).
It also indicates the sample size, type of study, type and dose
of omega-3 FA administered, major inflammatory biomarkers
determined and main outcomes.
Healthy individuals
Out of the 26 selected articles, 10 reported data on the effect of
dietary omega-3 FA on inflammatory biomarkers in healthy
participants(18–40). Quality scores for these studies ranged
from 3 to 5 for the JADAD scale, and from good to excellent
(G-E) for the CONSORT scale. All 10 studies were in healthy
adults (sample sizes from 12 to 161): three in young adults
(19–40 years), six in the middle-aged (40–65 years) and one
in the elderly (.65 years). Two of these studies investigated
the effects of omega-3 dietary supplementation on exercise-
induced markers of inflammatory mediators in exercise-trained
men(19,25) (Table 2). In eight of these studies, omega-3 was
delivered in fish oil capsules at daily doses of 0·12–2·22 g of
EPA and 0·26–0·56 g of DHA, alone or in combination, for
2–26 weeks. One study supplied 0·6 g EPA and 0·2 g DHA
daily in supplemented soybean milk for 12 weeks, while
another provided 2 ml/day of New Zealand Green Lipped
Mussel (97mg EPA and 72mg DHA) and 2ml/day of fish oil
(87mg EPA and 50mg DHA), administered using a dropper.
Only one study investigated the effect of parenteral lipid infu-
sion (4·55–9·8 g EPA þ4·9–10·9 g DHA), for a period of 48 h
and with cross-over repetition of the infusion after 3 months.
Inflammation outcome variables in the above studies
were serum markers, including CRP, cytokines (IL-1a, IL-1b,
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF-a,
interferon-g), chemokines (CCL2, CCL3, CCL5, CCL11) and
soluble forms of cell adhesion molecules (ICAM-1, VCAM-1,
E-Selectin). Four of the studies investigated the effects of
omega-3 supplementation on peripheral blood cell levels of
inflammatory markers induced by lipopolysaccharides (LPS)
or endotoxins, including eicosanoids (PGE1, PGE2, LTB4)
and cytokines (IL1 b, IL 6, IL 8, IL10 and TNF-a). Only one
study measured the expression of adhesion molecules in
monocytes (CD11b, CD18, CD49, CCR2 and CCR5).
Five studies determined the effect of omega-3 supplemen-
tation on serum CRP levels in healthy individuals, with one
report detecting no effect in healthy volunteers without
active inflammation, whereas another found lower exercise-
induced serum CRP levels after EPA/DHA supplementation
in trained men(26).
Omega-3 supplementation did not significantly affect the
serum concentration of any of the cytokines and chemokines
analysed in healthy individuals, with the exception of a
reduction in exercise-induced TNF-a(26).
Plasma soluble forms of cell adhesion molecules were
measured in three of these studies(18,20,24), finding no effects
except for a decrease in sICAM-1(20) and sVCAM-1(24) after
supplementation with 1·8 g EPA plus 0·3 g DHA (8 weeks)

























Fig. 1. Main stages of the systematic review.
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3·5 g/day fish oil (1·5 g/day total
n-3 PUFA); 12 weeks
IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-
8, IL-10, IL-12p70, IL-13, TNF-a,
Interferon-y, CCL2, ICAM-1,
VCAM-1, CCL3, CCL5, CCL11





VG n 111; (High EPA ¼ 36; Low





High-dose: 1·8 g EPA þ DHA;
Low-dose: 0·4 g DHA þ EPA;
HOSF; 26 weeks
Inflammatory gene expression. Intake of EPA þ DHA for 26 weeks can
change the gene expression profile of




VG n 21; (Exptal ¼ 10;
Placebo ¼ 11); Healthy
middle-aged men
(43·7 ^ 2·3 years;




EPA ¼ 1·8 g/d þ DHA ¼ 0·3 g/d; 8
weeks
IL-6, sE-Selectin, sICAM-1, sVCAM-
1, CRP, - sP-Selectin.
Marine oil providing 1·8 g EPA plus
0·3 g DHA/day is not sufficient to
demonstrate marked anti-inflamma-





VG n 30; (Exptal ¼ 15;
Placebo ¼ 15); Healthy
adults (27·8 ^ 1·2 years;




3 capsules (total: 0·24 g/d ALA,
0·12 g/d EPA, 0·49 g/d STA and
0·73 g/d GLA); 2 weeks
IL-8, IL-10, TNF-a, PGE1, PGE2,
LTB4.




G n 161; (Exptal ¼ 81;
Placebo ¼ 76) Healthy
middle-aged adults
(38·8 ^ 11·6 years;




EPA ¼ 0·60 g/d þ
DHA ¼ 0·26 g/d; 12 weeks
hsCRP, sTNF-Rs 1 and 2. Fish oils do not change inflammatory
parameters such as hs-CRP and





G n 30; (Exptal ¼ 12;
Control ¼ 13) Healthy
adults (43 ^ 10 years;




2 ml NZGLM oil(EPA ¼ 0·097 g/d
and DHA ¼ 0·072 g/d) and 2 ml
fish oil (EPA ¼ 0·087 g/d and
DHA ¼ 0·05 g/d); 6 weeks
PGE2, IL-1b and TNF-a. Low dose supplementation with n-3
LC-PUFA from two different marine
oil preparations showed no differ-
ence in inflammatory markers in this









EPA ¼ 4·55 - 9·8 g/d þ
DHA ¼ 4·9 – 10·9 g/d; 2 periods
of 48 hours (See note 1)
CD11b, CD18, CD49, CCR2 and
CCR5
A fish oil-based omega-3 lipid
emulsion significantly suppresses
monocyte proinflammatory cytokine










9 capsules/day(EPA ¼ 0·72 g/d þ
DHA ¼ 0·28 g/d); 12 weeks
Leukocytes, TNF-a, IL-1b, IL-6,
sICAM-1, sVCAM-1, sE-Selectin.
A moderate increase in consumption
of long-chain n-6 or n-3 PUFA does
not significantly affect inflammatory
cell numbers or neutrophil and
monocyte responses in humans and




G n 23; (Exptal ¼ 11;
Placebo ¼ 12); Healthy
endurance athletes
(24·1 ^ 2·4 years;




4 capsules (EPA ¼ 2 g/d þ DHA
0·4 g/d);6 weeks
CRP, Creatine kinase, IL-1,
IL-6, IL-8.
2·4 g/d EPA and DHA supplementation
for 6 weeks by trained cyclists did
not improve 10-km time-trial
performance or alter inflammation or
immunity before or after 3 days of
prolonged and intensive exercise
when compared with placebo.
Bloomer et al.
(2009) USA
G n 15; Healthy exercise






EPA ¼ 2·224 g/d þ
DHA ¼ 2·208 g/d; 6 weeks
CRP, TNF-a. EPA/DHA supplementation increases
blood levels of these fatty acids and
results in decreased resting levels
of inflammatory biomarkers in exer-
cise-trained men, but it does not
appear necessary for exercise-
induced attenuation in either inflam-
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VG n 121; (Exptal ¼ 60;






EPA ¼ 0·81 g/d þ
DHA ¼ 0·675 g/d; median of 21
days
Macrophage and T lymphocytes in
Carotid Plaque, mRNA of MMP-7,
MMP-9, MMP-12, IL-6, ICAM-1,
TIMP-2
Advanced atherosclerotic plaques
appear to readily incorporate EPA
from n-PUFA ethyl esters, and a
higher content of EPA in carotid
plaques is associated with a
reduced number of foam cells and T




VG n 76; (Exptal ¼ 38;






2 g n-3 PUFA (EPA ¼ 0·18 g þ
DHA ¼ 0·12 g) as ethyl esters
per gram/day; 3 months
hsCRP, TNF-a, IL-6, ICAM-1,
VCAM-1
n-3 PUFA can decrease plasma levels
of the pro-inflammatory
cytokines IL-6, TNF-a and ICAM-1
in patients with chronic heart failure
and can reduce plasma NT-proBNP
concentrations as biomarkers of risk




G n 20; (Exptal ¼ 10;





Concentrated ethyl ester 6 g/d; 2
months
PAI-1 Monocyte reactivity, PAI-1, fibrinogen
and TAT increased significantly
after surgery. These changes were
not modified by preoperative









Modification of n-6/n-3 ratio in a
high-saturated fatty acid oral fat
tolerance test; 3 trial days
CRP, IL-6, sIL-6R. Increasing the n-3 PUFA content of a
high-SFA OFTT does not acutely
change postprandial TAG or










1 g capsule/day (EPA ¼ 1·3 g/d þ
DHA ¼ 2·9 g/d);12 weeks
a1-antichymotrypsin, fibrinogen, PAI-
1, orosomucoid AGP, CRP, IL-6.
Habitual inflammatory status
influences the impact of n-3
LC-PUFA supplementation, but it is
not clear whether the effect of these











DHA ¼ 1·2 g/d; 6 weeks. CRP DHA supplementation restores
endothelial-dependent FMD in
hyperlipidaemic children. Hence, the
endothelium may be a




G n 59; (Exptal EPA ¼ 17;
Exptal DHA ¼ 17;





4 g/d of EPA(96 %) þ DHA
(92 %); 6 weeks
CRP, TNF-a, IL-6 Fall in urinary F2-isoprostane excretion
following 6 weeks of
purified EPA or DHA, suggesting










EPA ¼ 0·85 g/d and
DHA ¼ 3·4 g/d; 8 weeks
CRP, TNF-a, IL-6, IL-1b The 3·4 g/d dose of EPA þ DHA
significantly lowered triglycerides,
but neither dose improved
endothelial function or inflammatory
status over 8 weeks in healthy
adults with moderate hypertriglyceri-
demia.




E n 33; (Exptal ¼ 18;
Control ¼ 15) End-stage
renal disease (57·2 ^ 12·8





EPA ¼ 0·96 g/d þ DHA ¼ 0·6 g/d;
6 months
CRP Consuming 0·96 g/d of EPA and
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E n 42; (Exptal ¼ 26;
Control ¼ 16) Chronic
renal disease (55 ^ 8
years)
RCT Type 2·4 g/d n-3 PUFA; 2 months IL-6, TNF-a. A dietary regimen with fish oil could be
used in dialysis patients to slow






G n 38; (Exptal ¼ 18;
Placebo ¼ 20); Alzheimer’s
Disease (72·2 ^ 8·8 years,




EPA ¼ 0·15 g/d þ
DHA ¼ 0·43 g/d; 6 months
IL-6, TNR-a, sIL-1RII, CRP, APOE
genotype (possible relationship)
Treatment of AD patients with
omega-3 FA for 6 months did not
influence inflammatory biomarkers




E n 25; (Exptal ¼ 9;
Placebo ¼ 12); Alzheimer’s




EPA ¼ 0·6 g/d þ DHA1·7 g/d;
6 months
IL-6, IL-1b, TNF-a, IL-2,IL-4,IL-5,
IL-8, IL-10, Interferon-?
AD patients treated with DHA-rich n-3
FA supplementation increased
plasma concentrations of DHA and
EPA, which were associated with





E n 23; (Exptal ¼ 10;




6·4 g/d fish oil (Average 1·6 g
EPA/day þ0·7 g DHA/ day); 5
days
PGE2, Leukotriene, IL-1b, IL-6, IL-10
and TNF-a.
Inclusion of fish oil in parenteral
nutrition of septic ICU patients
increases plasma EPA, modifies
inflammatory cytokine concentration




VG n 10; (Exptal ¼ 5;




EPA ¼ 5·2–11·2 g þ
DHA ¼ 5·6–12·4 g; 10 days
(See note 2)
CRP, Leukocytes. Omega-3 and omega-6 lipid emulsions
differentially influence the plasma









EPA ¼ 4·55–9·8 g/d þ
DHA ¼ 4·9–10·9 g/d; 5 days
(See note 3)
IL-1b, IL-6, IL-8, IL-10, TNF-a, Use of lipid infusions and intravenous




E n 40; (Exptal ¼ 20;






0·15–0·2 g/kg/d fish oil (10 %
Omegaven); 5 days
CRP PN supplemented with omega-3 FA
diminishes the hyperinflammatory
response in severe acute
pancreatitis.
Note 1 Equivalent to 350 ml of 10 %
Omegaven
Note 2 Equivalent to 400 ml of 10 %
Omegaven
Note 3 Equivalent to 350 ml of 10 %
Omegaven
Footnote: NA, Not Available. Exptal, Experimental. EPA, Eicosapentaenoic Acid. DHA, Docosahexaenoic Acid. PGE1, Prostaglandins E1. PGE2, Prostaglandins E2. LTB4, Leukotriene B4. TNF-a, Tumour Necrosis Factor alpha. IL,
Interleukin. CRP, C-Reactive Protein. ICAM, Inter Cellular Adhesion Molecule. VCAM, Vascular Cell Adhesion molecule. NA, Not Available. Exptal, Experimental. EPA, Eicosapentaenoic Acid. DHA, Docosahexaenoic Acid.
PGE1, Prostaglandins E1. PGE2, Prostaglandins E2. LTB4, Leukotriene B4. TNF-a, Tumour Necrosis Factor alpha. IL, Interleukin. CRP, C-Reactive Protein. ICAM, Inter Cellular Adhesion Molecule. VCAM, Vascular Cell Adhesion
molecule, NZGLM, New Zealand Green Lipped Mussel. NA, Not Available. Exptal, Experimental. EPA, Eicosapentaenoic Acid. DHA, Docosahexaenoic Acid. PGE1, Prostaglandins E1. PGE2, Prostaglandins E2. LTB4, Leukotriene
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and 0·72 g EPA plus 0·28 g DHA (12 weeks), respectively. This
fish oil supplementation significantly decreased the release of
PGE1 and LTB4 alone after ex vivo LPS stimulation
(21), whereas
parenteral omega-3 lipid emulsion significantly suppressed the
generation of TNF-a, IL-1, IL-6 and IL-8 by monocytes in
response to LPS, although their surface expression of relevant
adhesive molecules was unchanged(39). Finally, only the study
by Bouwens et al.(20) examined the effect of omega-3 intake
on gene expression in peripheral blood mononuclear cells
(PBMCs), finding that EPA þ DHA intake reduced the
expression of genes involved in inflammatory-related path-
ways, such as nuclear transcription factor kB (NF- kB) signal-
ling and eicosanoid synthesis.
Cardiovascular disease
Eight of the articles selected in this review addressed the effect
of omega-3 LC-PUFA on inflammatory molecules as bio-
markers of CVD risk(27–33,41), with quality scores ranging
from 3 to 5 for the JADAD scale and from good to excellent
(G-E) for the CONSORT scale. Seven of these studies were
in adults (.18 years) and only one was in hyperlipidaemic
children and young people (9–19 years)(31). The study popu-
lations in the eight selected studies comprised: chronic heart
failure patients with presence or high risk of CVD (28); patients
awaiting carotid endarterectomy(27); patients undergoing cor-
onary bypass surgery(41), patients with metabolic syndrome(29)
or type 2 diabetes(32); overweight individuals(30) and people
with moderate hyperlipidaemia but otherwise healthy(33).
All studies in this section used capsules to supply EPA and
DHA, alone or combined, except for a postprandial study that
administered an oily supplement (1g fat per kg body weight)
containing 2·25% EPA plus 0·98% DHA in a high omega-3
PUFA blend or 0·37 EPA plus 0·16 DHA in a low omega-3 PUFA
blend(29). When combined, EPA and DHA doses ranged from
0·6 g/d (0·36 g/d EPA plus 0·24 g/d DHA)(28) to 6 g/d(41) for 12
weeks. When administered alone, the regimen was 3·68 g/d
DHA for 13 or 6 weeks and 3·84 g/d of EPA for 6 weeks(32).
Outcome variables in the studies in this group were cytokines
(IL-1b, IL-2, IL-6 and IL-6 soluble receptor, IL-8, IL-10, TNF-a,
TNF-R1, TNF-R2); serum markers, including CRP, a1-antichymo-
trypsin (ACT), fibrinogen, tissue factor pathway inhibitor (TFPI),
tissue plasminogen activator inhibitor (PAI-1), thrombin-antith-
rombin III (TAT) complexes, a1-acid glycoprotein (AGP) and
sialic acid; MMP2; soluble adhesion molecules (ICAM-1,
VCAM-1, E-Selectin), pro-brain natriuretic peptide (NTproBNP),
serum amyloid A (SAA), granulocyte colony stimulating factor
(G-CSF) and granulocyte monocyte-colony stimulating factor
(GM-CSF). There were also assessments of the expression of
IL-6, IL-10, TNF-a, ICAM-1, MMP3, MMP7, MMP8, MMP9,
MMP12, MMP13, TIMP1, TIMP2 and 36B4 in plaque cells(27)
and of IL-1b, IL-6 and TNF-a in mononuclear cells(33).
Omega-3 supplementation did not significantly affect the
serum concentration of cytokines and chemokines with the
exception of IL-6 and TNF-a. IL-6 levels, which were lower
after omega-3 PUFA in two of the studies(28,30). Cawood
et al.(27) reported a decreased expression of IL-6 mRNA in
plaque cells, whereas Mori et al.(32) and Tulk et al.(29 )found
no significant effect on this cytokine. Lower TNF-a plasma
levels were reported by Zhao et al.(28) after omega-3 PUFA,
but this reduction was not observed by Mori et al.(32).
A decrease in CRP was reported after 12 weeks of omega-3
supplementation(30), but no such effect was found by Mori
et al.(32), Zhao et al.(28), or Skulas-Ray et al.(33). Zhao et al.(28)
observed an association between omega-3 LC-PUFA sup-
plementation and decreased plasma levels of high sensitive
CRP (hsCRP), especially among smokers, while another study
found the postprandial CRP response to be similar after intake
of a low or high omega-3 PUFA dose(29). With regard to
adhesion molecules, one study showed lower plasma ICAM-1
levels(28). Finally, analyses of cell gene expression showed
that supplementation with EPA plus DHA significantly reduced
mRNA levels of MMP7, MMP9, MMP12, IL-6, ICAM-1 and TIMP-2
in plaque cells(27) but had no effect on mononuclear cell gene
expression of IL-1b, IL-6 or TNF-a(33).
Other chronic diseases
Effects of omega-3 FA on inflammatory markers were studied
in chronic renal disease patients undergoing haemodialysis in
two of the selected articles(34,35) and in patients with Alzhei-
mer’s disease (AD) in another two(36,37). The quality scores
for these articles ranged from 3 to 5 for the JADAD scale
and from very good to excellent (V-E) for the CONSORT scale.
In the Bowden et al. study(34), eligible patients undergoing
chronic haemodialysis maintenance were randomly assigned to
an omega-3 (experimental, n 18) or corn oil (control, n 15)
group. The experimental group received 960 mg EPA/d plus
600mg DHA/d orally for 6 months, which had a significant
effect on CRP levels not observed in the placebo group. Peru-
nicic-Perovic et al.(35) examined 42 haemodialysis patients and
16 healthy controls, administering the patients with daily sup-
plements of 2·4 g omega-3 LC-PUFA (180mg EPA and 120 mg
DHA) for 2 months, and reported a significant decrease in inflam-
matory markers (IL-6 and TNF-a) in the supplemented group.
Vedin et al.(37) carried out an RCT in 174 AD patients who
received 1·7 g DHA plus 0·6 g EPA or placebo for 6 months.
The omega-3 group showed significant decreases in IL-6,
IL-1 and G-CSF secretion after LPS stimulation of PBMCs. In
addition, increases in the concentrations of DHA and EPA
were negatively associated with IL-1 and IL-6 release in all
of the patients. However, no decrease in the secretion of
TNF-a, IL-8, IL-10, or GM-CSF was observed. Freund-Levy
et al.(36) found that omega-3 FA treatment for 6 months did
not influence inflammatory biomarkers in cerebrospinal fluid
(CSF) or plasma of patients with mild to moderate AD. In
their study, 35 patients were randomly assigned to a daily
intake of 2·3 g omega-3 FA or placebo for 6 months, analysing
CSF and plasma levels of IL-6, TNF-a and soluble IL-1 receptor
type II at baseline and 6 months.
Acute diseases
Three of the selected articles studied the effects of omega-3 FA
on inflammatory biomarkers in septic patients(23,38–39) and one
investigated them in patients with severe acute pancreatitis(40).
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Their quality scores ranged from 3 to 5 for the JADAD scale
and from very good to excellent (V-E) for the CONSORT
scales, respectively.
The studies in septic patients were randomised but single
blind(38) or open label(23,39). The treatment was short (5–7
days) in all three studies, and the omega-3 LC-PUFA dose
ranged from 6·4 to 23·6 g/d. In the study by Barbosa et al.(38),
parenteral administration of fish oil emulsion significantly
decreased IL-6 levels, with a parallel increase in IL-10, and
improved the gas exchange, finding a tendency to a shorter
hospital stay in patients receiving this supplementation.
Mayer et al.(23) studied 21 patients with sepsis requiring par-
enteral nutrition, who were randomised to receive an omega-3
lipid emulsion rich in EPA and DHA or a conventional omega-
6 lipid emulsion for 5 days. Generation of proinflammatory
cytokines by mononuclear leukocytes was markedly amplified
by omega-6 lipid intake and suppressed by omega -3 intake.
Mayer et al.(39) also studied ten patients with septic shock
and eight healthy controls. Patients requiring Parenteral
Nutrition (PN) received intravenously an omega-3 or omega-
6 lipid emulsion (five per group) for a 10-day period. With
the omega-6 lipid infusion regimen, the impairment of neutro-
phil functions persisted or worsened, whereas LTB5 and LTB4
appeared upon neutrophil stimulation in the omega-3 lipid
group and neutrophil function was significantly improved.
Wang et al.(40) performed an RCT in 47 severe acute pan-
creatitis patients randomly assigned to receive PN for 5 days
with identical amounts of amino acids, glucose and fat but
different lipid compositions. The control group received a soy-
bean oil based emulsion and the omega-3 FA group was sup-
plemented with 0·15–0·2 g/kg/d fish oil. Fish oil-treated
patients had significantly lower CRP levels and blood cell
counts after 5 days of PN.
Discussion
Omega-3 FA supplementation is known to lower inflammation
biomarkers in the plasma and cells of patients with acute and
chronic diseases, but its effect on healthy subjects is less well
documented. Numerous authors have studied the combined
effects of EPA and DHA but only a few have administered
EPA or DHA alone. In addition, very few studies have investi-
gated the effects of these FA on in vivo cell inflammatory bio-
markers, on ex vivo cytokine release or on the expression of
genes related to inflammation cascade signalling.
Healthy subjects
In the studies of healthy participants selected in this review,
omega-3 supplementation generally had no effect on inflam-
matory biomarkers, which may be due to their low levels in
serum, minimizing the possibility of their reduction through
the intake of fish oil.
Fish oil supplementation was found to have only isolated
effects on plasma soluble forms of cell adhesion molecules,
reducing sICAM-1(20) and sVCAM-1(24) levels. The stronger
association of DHA changes than EPA changes with sICAM
described by Yusof et al.(20) suggested that DHA may be
more anti-inflammatory than EPA. However, this hypothesis
was ruled out by the neutral effect on sICAM found by
Thies et al.(24), who used a very similar dosage of DHA
(0·28 g vs. 0·3 g) alone or in combination with 0·72 g EPA
during a longer period (12 vs. 8 weeks) and only found an
influence on sVCAM-1 levels. The different effects of omega-
3 on sICAM-1 and sVCAM-1 concentrations may suggest that
VCAM-1 and ICAM-1 are regulated by different mechanisms
and are not equally sensitive to n-3 PUFA.
The release of cytokines after ex vivo LPS stimulation was
not affected by oral administration of omega-3(21,24–42). How-
ever, in a study of healthy volunteers with a cross-over design,
a decrease in LPS after parenteral administration of omega-3
lipid emulsion(39) induced the production of cytokines (TNF-
a, IL-1, IL-6 and IL-8), demonstrating that a short (48 h) infu-
sion with omega-3 lipids is sufficient to significantly suppress
monocyte proinflammatory cytokine generation. PN studies in
healthy volunteers are rare and ethically questionable, making
it impossible to draw conclusions about the anti-inflammatory
effect of omega-3 in this situation.
Findings of the pioneering study by Bouwens et al.(19)
opened up a new approach for research into the effects of
omega-3, demonstrating the potential of PBMC gene
expression profiling for determining the effects of nutrition
on human health status. However, this study was performed
in elderly individuals, who are likely to express a slightly
more proinflammatory gene expression profile, given that
aging is associated with a chronic, low-grade elevation of
inflammatory activity(43). Therefore, the results cannot be gen-
eralised to the whole population, and further research is
required to confirm these findings in other age groups.
One way to investigate the effect of omega-3 supplemen-
tation on inflammatory markers in healthy individuals is to
stimulate the inflammatory response by exercise. Transient
inflammation and immune dysfunction are part of the
normal human response to prolonged and intense exercise
and are characterised in part by the production of inflamma-
tory cytokines, acute-phase proteins and oxidative stress
from reactive oxygen species, as well as by alterations in
innate and adaptive immunity(42,44). However, conflicting
results were published by two studies of inflammation. One
found decreased levels of exercise-induced CRP, TNF-a and
IL-6 after omega-3 supplementation(26), whereas the other
observed no change in these levels(25). Discrepancies may
be due to differences in the training status of participants,
the duration of supplementation, the dose and FA composition
of the n-3 PUFA administered, and the exercise protocol used.
Thus, the two aforementioned studies(25,26) differed in the
total daily dosage of DHA (2208 mg vs. 400 mg) and exercise
protocol (3 h/d cycling for 3 days vs. treadmill walking with
weighted backpack for 60 min). The omega-3 supplemen-
tation was unable to counteract the acute inflammatory
response induced in the former study, while it had no effect
on the very weak inflammatory response induced by exercise
in the latter, with the exception of decreased CRP and TNF-a
levels at rest. In conclusion, the exercise-related omega-3-sup-
plementation studies included in this review do not provide
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strong evidence of anti-inflammatory effects in trained or
untrained participants.
Cardiovascular diseases
Results of selected articles on the effect of omega-3 LC-PUFA
on inflammatory molecules as biomarkers of CVD risk remain
inconclusive, and further studies are required. The evidence
of clinical efficacy is not strong enough to make final
recommendations for a specific dose or duration of
supplementation.
The only inflammatory biomarkers affected by omega-3
PUFA in multiple studies were IL-6 and CRP, while TNF-a,
sICAM-1 and GM-CSF were decreased in single studies. No
effects on plasma biomarkers were found when omega-3
PUFA was administered for less than 12 wks, even at high
doses, as shown by Nilsen et al.(41) and Mori et al.(32). However,
shorter treatments may possibly induce changes in the mRNA
expression of selected inflammatory genes by specific cells
without affecting plasma levels, as observed by Cawood et al.(27)
There is no consensus on the doses required to exert an
anti-inflammatory effect, given that limited positive effects
have been observed after low(28) or high(30) doses. It is there-
fore not possible to identify the dose needed to obtain an
anti-inflammatory effect in patients with CVD risk.
In relation to the type of FA, most studies administered
a combination of EPA plus DHA, and only Mori et al.(32) com-
pared the effects of EPA versus DHA supplementation (for
6 weeks), reporting that neither had a significant effect.
Hence, there is inadequate evidence to establish whether
cardiovascular inflammation can be reduced by EPA or DHA
or by the synergic effects of both.
Two of the studies showing an impact on IL-6 after omega-3
supplementation were reported to have inadequate power to
detect a significant effect on inflammatory status, due to their
small sample sizes (n 32, Browning et al., 2006, and n 38,
Zhao et al., 2009)(28,30). The same limitations apply to the
effects on CRP, whose reduction was reported in the same
studies. Specifically, Zhao et al.(28) found omega-3 LC-PUFA
to be associated with a decrease in plasma CRP levels in smo-
kers but not in non-smokers. Although there is no consensus
on the reproducible effects of cigarette smoke, it appears evi-
dent that smoking can increase the inflammatory response(45),
and the results obtained by Zhao et al.(28) suggest that smo-
kers, with an increased inflammatory status, may take greater
advantage of the anti-inflammatory effects of omega-3 PUFA.
Finally, the postprandial inflammatory response after an oral
fat tolerance test was not modified by increasing omega-3
PUFA content, indicating that omega-3 PUFA does not have
an acute effect and must be incorporated into cell membranes
before exerting an anti-inflammatory effect.
Based on the results related to CVD risk examined in this
review, there is inadequate evidence to establish a relationship
between the consumption of omega-3 LC-PUFA and beneficial
inflammatory biomarker outcomes, probably due to discre-
pancies in protocols, doses and treatment times. Further
research is necessary to standardize protocols and determine
suitable doses and regimens.
Other chronic diseases
Only two RCTs studied inflammatory biomarkers in AD, with
contradictory results. Omega-3 FA affected the release of
cytokines from blood mononuclear leukocytes but did not
influence inflammatory biomarkers in CSF(37), although the
correlation between soluble IL-1 receptor II (sIL-1RII) and
amyloid peptide Ab1-42 may reflect reciprocal interactions
between IL-1 and Ab peptides(36). However, it remains to
be established whether omega-3 FA attenuate the release of
cytokines from brain cells in AD.
CVD is a comorbid condition in patients with end-stage
renal disease (ESRD) and is associated with a high mortality
rate. The CVD risk in patients undergoing chronic haemo-
dialysis can be ascribed to elevated serum lipid levels and
blood pressure, although additional factors (e.g., acute
phase reactants) may lead to a risk profile that is 10- to
20-fold higher in comparison to apparently healthy individuals
and is responsible for the very high (50 %) annual mortality in
ESRD patients(46).
The use of omega-3 LC-PUFA has been proposed to control
endothelial dysfunction and thereby control CRP levels.
Additionally, ESRD patients do not usually consume enough
omega-3 FA in their diet(47). The consumption of 960 mg/d
of EPA and 600 mg/d of DHA can lower CRP in ESRD patients,
even though there is no clinically significant change in
their triglyceride levels(34). Furthermore, ESRD patients on
haemodialysis who received 2·4 g of n-3 LC-PUFA per day
for 2 months exhibited a significant decrease in inflammatory
markers (IL-6 and TNF-a)(35). However, compliance was
not assessed. Further studies in ESRD patients are required
to identify a complete set of biomarkers involved in
inflammation.
Acute diseases (Critically ill patients)
In the cascade of inflammatory response during the acute
phase of severe acute pancreatitis, PN supplemented with
omega-3 FA is a treatment option for patients with systemic
inflammatory response syndrome (SIRS) or sepsis complicated
by multiple organ failure(48). After 5 days of PN plus omega-3
FA, severe acute pancreatitis patients had significantly
lower CRP levels and blood white cell counts and showed
improved respiratory function and shortened continuous
renal replacement therapy time, suggesting that the systemic
response to pancreatic and organ injury is attenuated by
omega-3 LC-PUFA(40).
Omega-3 FA are thought to suppress inflammation and ame-
liorate the course of infection by reducing proinflammatory
eicosanoids and cytokines. However, only one RCT assessed
CRP changes, and further experimental studies and clinical
trials are needed to establish the appropriate doses of
omega-3 LC-PUFA and the specific effects of EPA and DHA
on inflammatory biomarkers.
Novel potent lipid mediators derived from LC-PUFA, arachi-
donic acid (AA), EPA and DHA, namely lipoxins, resolvins,
and protectins, have been identified in resolving exudates
over recent years, and their biosynthetic pathways and actions
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have been described. Their activity is likely to account in part
for some of the immunoregulatory and disease-modifying
actions attributed to dietary omega-3 LC-PUFA(49). However,
no controlled studies in humans have evaluated the influence
of omega-3 FA on these new lipid mediators.
Dietary recommendations of n-3 LC-PUFA in health and
disease
A recent report of the FAO has established that for adult males
and non-pregnant/non-lactating adult females 0·250 g/d of
EPA plus DHA is recommended, with insufficient evidence
to set a specific minimum intake of either EPA or DHA
alone(50). The upper value of acceptable macronutrient distri-
bution range for EPA þ DHA consumption has been set at 2 g/
d due to experimental evidence indicating that high sup-
plement intakes of n-3 LC-PUFA may increase lipid peroxi-
dation and reduce cytokine production. However, it is
acknowledged that higher consumption values, as high as
3 g/d reduce some cardiovascular risk factors and have not
had adverse effects in short- and intermediate term random-
ised trials.
The American Heart Association (AHA) recommended 0,5
to 1 g/d of omega-3 EPA and DHA for individuals with border-
line fasting triglyceride levels (150 to 199 mg/dl), 1 to 2 g/d
for individuals with high fasting-triglyceride levels (200–
499 mg/dl), and 2 to 4 g/d for individuals with very high
fasting-triglyceride levels (.500 mg/dl)(51).
Based in our study of RCT, a moderate consumption of n-3
LC-PUFA (0·9 to 2 g/d) does not change inflammatory bio-
markers in healthy subjects(18–23). However, about 4 g/d of
EPA/DHA supplementation decreases resting levels of inflam-
matory biomarkers in exercise-trained men, but it does not
appear necessary for exercise-induced attenuation in either
inflammation or oxidative stress(25). n-3 PUFA intake of 1·2
to 6 g/d decrease plasma levels of the pro-inflammatory cyto-
kines and is associated with a reduced number of foam and T
cells in atherosclerotic plaques(27 )and with reduced levels of
some inflammatory biomarkers in plasma(28). However, there
is no consensus on the doses required to exert an anti-inflam-
matory effect(28–29). Regarding the effects of n-3 LC-PUFA on
inflammatory biomarkers in neurodegenerative diseases, AD
patients treated with DHA exhibit a reduced release of IL-
1b, IL-6 and granulocyte colony-stimulating factor from
PBMCs(37). Furthermore, in patients with chronic renal dis-
ease, the intake of 1·5 to 2·4 g of n-3 LC-PUFA decreases
CRP and other cytokines(34,35).
Omega-3 LC-PUFA are able to suppress inflammation and
ameliorate the course of infection by reducing proinflamma-
tory eicosanoids and cytokines in critically ill patients (40,48)
but further research is needed before definitive recommen-
dations can be made on doses and on the routine use of
omega-3 FA in the critically ill.
Despite n-3 fatty acids reduce the risk of cardiovascular
disease there has been concern that these fatty acids may
increase lipid peroxidation. However, post-intervention
urinary F2-isoprostanes were decreased by EPA and DHA in
type 2 diabetic patients(32). In addition, it has been reported
that supplementation with n-3 fatty acids decreases non-enzy-
matic free radical–catalyzed isoprostane formation in healthy
humans(52. Likewise, plasma free F2-isoprostane concen-
trations were lower after fish-oil supplementation than
after sunflower-oil supplementation in postmenopausal
women(53). In conclusion, 3–4 g of n-3 LC-PUFA intake does
not have an apparent effect on lipid peroxidation.
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52. Nälsén C, Vessby B, Berglund L, Uusitupa M, Hermansen K,
Riccardi G, et al. (2006) Dietary (n-3) fatty acids reduce
plasma F2-isoprostanes but not prostaglandin F2alpha in
healthy humans. J Nutr 136, 1222–1228.
53. Higdon JV, Liu J, Du SH, Morrow JD, Ames BN & Wander
RC (2000) Supplementation of postmenopausal women
with fish oil rich in eicosapentaenoic acid and docosahex-
aenoic acid is not associated with greater in vivo lipid per-
oxidation compared with oils rich in oleate and linoleate as
assessed by plasma malondialdehyde. Am J Clin Nutr 72,
714–722.


























ranada , on 10 Jun 2020 at 08:33:44 , subject to the Cam
bridge Core term
s of use, available at https://w
w
w
.cam
bridge.org/core/term
s . https://doi.org/10.1017/S0007114512001559
